Anbogen and BeiGene Join Forces to Explore Cancer Treatments
Anbogen and BeiGene Collaborate on Innovative Cancer Therapy
Anbogen, a clinical-stage biotech company, has announced a significant collaboration with BeiGene to evaluate a combination therapy for colorectal cancer. This partnership aims to leverage Anbogen's HDAC inhibitor, ABT-301, alongside BeiGene's anti-PD-1 antibody, tislelizumab. The focus of this initiative is on treating patients suffering from mismatch repair-proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) within a global Phase II trial.
Exploring the Unmet Needs in Colorectal Cancer Treatment
Globally, colorectal cancer remains a major health challenge, with over 1.9 million new cases diagnosed in 2020 alone. Current therapies, particularly immune checkpoint inhibitors (ICIs), have shown promise in treating patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). However, these therapies effectively serve less than 5% of mCRC cases, indicating a dire need for innovative solutions that address the 95% of patients with pMMR/MSS tumors that do not respond to traditional ICI therapies.
Potential Enhancements in Combination Therapy
ABT-301, Anbogen's novel HDAC inhibitor, has shown encouraging profiles in prior studies, demonstrating safety and favorable pharmacokinetics as a single agent. Furthermore, preclinical evidence suggests that ABT-301 may increase the efficacy of anti-PD-1 therapies. It does this by boosting CD8+ cytotoxic T cells and reducing the presence of monocytic myeloid-derived suppressor cells, both of which could enhance immune response against tumors while also inhibiting angiogenesis. This new research initiative will assess the treatment's effectiveness when ABT-301 is combined with tislelizumab, with and without Bevacizumab, for those pMMR/MSS mCRC patients who have significant unmet needs.
CEO's Vision for Collaborative Progress
John Hsu, the CEO of Anbogen, expressed enthusiasm for this partnership, stating, "We are excited to partner with BeiGene to investigate this promising combination therapy. ABT-301 has shown potential in preclinical studies, and we believe that combining it with tislelizumab could provide a new therapeutic option for patients with colorectal cancer." This collaboration highlights both companies' commitment to advancing cancer therapy.
Details of the Clinical Trial
This clinical trial will be carried out across multiple research centers, focusing on evaluating the safety, tolerability, and preliminary efficacy of the combination therapy in a specified cohort of patients with advanced MSS CRC. The enrollment for this promising study is anticipated to begin in the first quarter of the following year.
About Anbogen: Pioneering Cancer Treatments
Established by Dr. Joe Shih, Anbogen is dedicated to developing precision anti-cancer drugs, driven by a commitment to innovate and improve cancer treatment outcomes globally. The company recently completed a Series A funding round, raising US$20 million to support its research and development efforts. Currently, Anbogen focuses on two clinical-stage assets: ABT-101, aimed at treating non-small cell lung cancer (NSCLC) with specific HER2 mutations, and ABT-301, which is being evaluated for pMMR/MSS mCRC in combination with anti-PD-1 therapies.
Frequently Asked Questions
What is the main focus of Anbogen and BeiGene's collaboration?
The collaboration aims to evaluate the combination therapy of Anbogen's HDAC inhibitor ABT-301 with BeiGene's anti-PD-1 antibody tislelizumab for colorectal cancer patients.
What is ABT-301?
ABT-301 is a novel HDAC inhibitor that has shown promising safety and pharmacokinetic profiles in early-stage clinical studies for cancer treatment.
Who will the clinical trial target?
The clinical trial will target patients with mismatch repair–proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
When is the expected start date for patient enrollment in the trial?
Patient enrollment for the clinical trial is expected to begin in the first quarter of the following year.
What other assets is Anbogen developing?
In addition to ABT-301, Anbogen is also developing ABT-101 for non-small cell lung cancer (NSCLC) patients with HER2 exon20 insertion mutations.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Regulatory Challenges Hit Chevron-Hess Merger Amid FTC Restrictions
- Celebrating Euziel's 12 Years of Service and Expansion in Europe
- IDEAYA Biosciences Expands Its Team with Incentive Stock Grants
- GiGi's Playhouse Launches New Location to Inspire Community Growth
- Summary of Gotbit Hedge Fund's Impact at TOKEN2049 Event
- Summit Therapeutics Faces Rating Downgrade Due to Data Timing
- Future Prospects for Gold, Euro, and Bitcoin Amid Market Changes
- Market Insights: S&P 500 and Nasdaq Show Strong Potential
- Explore Top Stocks by Warren Buffett for Long-Term Growth
- China's Stock Market Rally Reflects Investor Optimism
Recent Articles
- Haakon Larsen Honored with 2024 Innovative CEO Award
- Namia River Retreat: Your Next Luxurious Getaway in Hoi An
- Shanghai Electric Showcases Innovative Solutions at CIIF 2024
- XCMG and Shell Forge Alliance Enhances Machinery Performance
- Exciting Events Unfold for 'Bleach: Brave Souls' Players
- Recent Advances in Treating Renal Impairment in Myeloma Patients
- Electric Vehicle Remote Diagnostics: Transformative Growth Ahead
- Commerzbank AG Shows Promise: 10% Growth Potential Ahead
- Navigating Market Trends: Will October Follow September's Path?
- European Stocks Soar as China Economic Stimulus Drives Rally
- Economic Shifts Stir Markets: S&P 500 Highs and Oil Declines
- Medius Secures Customer Favorite Recognition in 2024
- Desman Achieves Global Leadership in High-End Smart Locks
- Medius Achieves Customer Favorite Status by Spend Matters
- AI Technology Driving Growth in Municipal Water Equipment Market
- Concerns Rise Over Russian Drone Breaching Romanian Airspace
- Coca-Cola's Strategic Shift Drives Stock Growth and Market Confidence
- HSBC Upgrades Ageas Stock with Optimistic Growth Outlook
- European Markets Surge as STOXX 600 Achieves New Heights
- Civic and Rentality Innovate Car Rentals with Blockchain Security
- Unveiling the Passwords App in iOS 18: A Comprehensive Guide
- SpaceX's Starlink Surpasses 4 Million Users With Enhanced Service
- Carnival Corporation Reports Anticipated Q3 Earnings Changes
- Key Market Movers: Costs, Technology, and Education Stocks
- S&P 500 Reaches New Heights: Investor Sentiment Explodes
- Spain's Economic Growth Reaches 3.1% in the Second Quarter
- Navigating Challenges: TELUS Corporation's Stock Outlook
- ZTO Express Stock Sees Positive Trends in Volume and Profitability
- Sany Heavy Equipment Forecasts Increase in Revenue and Exports
- VersaBank Poised for Growth Following Major U.S. Expansion
- UBS Upgrades Certara Stock Amid Rising Biosimulation Demand
- Chesapeake Energy Positioned for Strong Growth Amid Market Changes
- Vista Oil & Gas Stock Receives Buy Rating Amid Growth Surge
- LVMH Strategically Acquires Stake in Moncler Through Double R
- NPCI Ventures into Trinidad and Tobago's Digital Payments Space
- XPeng Motors Benefits as China Implements New Stimulus
- Market Rally Fueled by Stimulus from China and Japan
- World of Dypians Achieves Milestone Recognition by Binance
- Municipality Finance Launches EUR 50 Million Note Offer
- Nexstim Expands Its Footprint in Finland with New Order
- Nykredit Realkredit A/S Finalizes Terms for New Note Issuance
- Geoquip Marine Welcomes Rune Olav Pedersen as New CEO
- Wolters Kluwer Introduces CCH iFirm Validate for Efficient Audits
- Photocure Launches Program to Enhance Bladder Cancer Care
- Van Leeuwen Pipe and Tube Group Receives Royal Honor for 100 Years
- Sineng Electric Makes Major Leap in U.S. Energy Storage
- September Brings Relief as French Inflation Slows Down
- Exploring Kamala Harris' Vision for a Fairer Economy
- VINCI Secures Major Highway Concession Amid Infrastructure Growth
- SES Plans Substantial Shareholder Returns with New Dividend